| 摘要 |
The invention provides a treatment of ovarian cancer, particularly ovarian cancer that is resistant to platinum-containing anti-cancer drugs, using an estrogen receptor β subtype (ERβ) agonist, wherein the treatment comprises administering the ERβ agonist to the patient, and administering a platinum-containing anti-cancer drug to the patient, the administrations being simultaneous, sequential or separate. The invention also provides an ERβ agonist and a platinum- containing anti-cancer drug for use in the treatment of ovarian cancer in a patient, wherein the treatment comprises administering the ERβ agonist to the patient, and administering the platinum-containing anti-cancer drug to the patient, the administrations being simultaneous, sequential or separate; a kit comprising an ERβ agonist, a platinum-containing anti-cancer drug, and a further compound suitable for the treatment of ovarian cancer; and an ERβ agonist for use in the treatment of ovarian cancer in a patient, or an ERβ agonist and a taxane for use in the treatment of ovarian cancer in a patient, wherein the treatment comprises administering the ERβ agonist to the patient, and administering a taxane to the patient, the administrations being simultaneous, sequential or separate. |
